Canadian drugmaker Valeant Pharmaceuticals (NYSE: VRX) has confirmed that executive vice president, company group chairman, Deb Jorn, has resigned from the company with immediate effect.
Ms Jorn was responsible for running the company’s US dermatology and gastrointestinal businesses.
In a statement the company confirmed that Eric Abramson, vice president dermatology and immunology marketing, has been appointed general manager of the US dermatology business and Dr Ari Kellen, executive vice president and company group chairman will oversee Valeant’s gastrointestinal business.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze